# Engineering Cells to Make Gene Therapy Viruses Using AAVrh.10

> This patent describes specific engineered cells that contain parts of the AAVrh.10 virus and an additional non-viral genetic sequence, designed to produce gene therapy vectors.

- **Patent:** US 11499167
- **Original title:** Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
- **Owner:** University of Pennsylvania
- **Granted:** 2022
- **Status:** Active
- **Times cited:** 0
- **Field:** biotech, pharmaceutical, gene_editing

## What it does

The patent claims a "cultured host cell" that has been genetically modified. This cell contains a "recombinant nucleic acid molecule" (an engineered piece of DNA) that carries instructions for two main things: first, making specific parts of the AAVrh.10 virus, such as its "vp1 capsid protein" (amino acids 1 to 738 of SEQ ID NO: 81), or vp2, or vp3, or specific nucleotide sequences (like 845 to 3058 of SEQ ID NO: 59); and second, a "heterologous non-AAV sequence." This "heterologous" part is the therapeutic genetic material that a gene therapy aims to deliver. For example, a cell could be engineered to produce the outer shell of the AAVrh.10 virus, while also carrying the gene for a missing protein in a patient. Some claims also specify the presence of a "functional rep gene" (which helps the virus replicate) and that the recombinant molecule can be a "plasmid" (a common way to introduce DNA into cells).

## What it does NOT cover

- Does not cover AAVrh.10 sequences or proteins existing outside of a cultured host cell.
- Does not cover host cells containing AAVrh.10 components without an additional "heterologous non-AAV sequence."
- Does not cover other types of adeno-associated viruses (AAVs) beyond the specific AAVrh.10 variant described.
- Does not cover gene therapy vectors that use entirely different viral or non-viral delivery systems.
- Does not cover cells containing only the AAV 'rep gene' without the specified capsid protein or nucleotide sequences.

## The clever bit

The novelty lies in precisely defining and claiming the use of specific AAVrh.10 capsid protein sequences (like VP1, VP2, VP3 from SEQ ID NO: 81) or specific nucleic acid sequences (from SEQ ID NO: 59) within a cultured host cell, specifically combined with a "heterologous non-AAV sequence" for gene delivery applications. This focuses on a particular, potentially advantageous, AAV serotype for vector production.

## Real-world examples

1. Manufacturing of gene therapy vectors in bioreactors
2. Research into new gene therapies for genetic disorders
3. Production of AAV-based vaccines in laboratory settings

## Why it matters

Adeno-associated viruses (AAVs) are widely used in gene therapy because they can deliver genetic material into cells safely and efficiently. The University of Pennsylvania, particularly through Dr. James Wilson's lab, has been a pioneer in identifying and developing different AAV serotypes, like AAVrh.10, which can have unique properties for targeting specific tissues or evading immune responses. This patent protects the specific engineering of cells to produce gene therapy vectors using this particular AAVrh.10 variant, which is crucial for developing new treatments for genetic diseases.

## Frequently asked questions

### What does Engineering Cells to Make Gene Therapy Viruses Using AAVrh.10 cover?

This patent describes specific engineered cells that contain parts of the AAVrh.10 virus and an additional non-viral genetic sequence, designed to produce gene therapy vectors.

### Who owns patent US 11499167?

University of Pennsylvania owns this patent, granted in 2022.

### When does this patent expire?

This patent is expected to expire on October 12, 2041, when the invention enters the public domain.

### What problem does this patent solve?

Adeno-associated viruses (AAVs) are widely used in gene therapy because they can deliver genetic material into cells safely and efficiently. The University of Pennsylvania, particularly through Dr. James Wilson's lab, has been a pioneer in identifying and developing different AAV serotypes, like AAVrh.10, which can have unique properties for targeting specific tissues or evading immune responses. This patent protects the specific engineering of cells to produce gene therapy vectors using this particular AAVrh.10 variant, which is crucial for developing new treatments for genetic diseases.

### What does this patent NOT cover?

Does not cover AAVrh.10 sequences or proteins existing outside of a cultured host cell.

**Full plain-English explainer:** https://patentbrief.org/patent/us/11499167/method-of-detecting-andor-identifying-adeno-associated-virus-aav-sequences-and-i

**Original patent:** https://patents.google.com/patent/US11499167

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._


## Related patents

Semantically similar inventions in the PatentBrief corpus:

- [New Adeno-Associated Virus Capsids for Gene Therapy](https://patentbrief.org/patent/us/11357868/adeno-associated-virus-aav-clades-sequences-vectors-containing-same-and-uses-the) — This patent describes new types of adeno-associated virus (AAV) capsids and how to use them in cells to deliver genes for therapies or vaccines.
- [Engineered AAV Vectors for Targeted Gene Delivery to Specific Body Parts](https://patentbrief.org/patent/us/12735721/engineered-adeno-associated-aav-vectors-for-transgene-expression) — This patent describes specially designed adeno-associated virus (AAV) vectors that can deliver new genetic material to specific tissues in the body, such as the brain, heart, or retina, to treat diseases.
- [Treating Muscular Dystrophy with a Self-Complementary AAV Gene Therapy](https://patentbrief.org/patent/us/12735723/self-complementary-adeno-associated-virus-vector-and-its-use-in-treatment-of) — This patent describes a method to treat muscular dystrophy by delivering a specific gene using a specially designed, self-complementary adeno-associated virus (AAV) vector.
- [How to Make Human Erythropoietin (EPO) Using Engineered DNA](https://patentbrief.org/patent/us/4703008/neupogen-g-csf-filgrastim) — This patent describes the specific DNA sequences and methods to engineer cells to produce erythropoietin (EPO), a protein vital for red blood cell production, outside the human body.
- [How Engineered TALE Proteins Can Edit Genes](https://patentbrief.org/patent/us/11661612/dna-binding-proteins-and-uses-thereof) — This patent describes engineered DNA-binding proteins called TALEs, which are shortened and modified to precisely target and edit specific DNA sequences in cells, potentially for gene therapy.
